BioSpace News Archive

Ecolab Inc. will begin implementing a price increase for all Life Sciences division offerings, effective February 1, 2022, due to the significant and ongoing global supply chain disruptions and cost increases, including those for raw materials, logistics and labor.

Transcat, Inc. announced that it will release its third quarter fiscal year 2022 results after the close of financial markets on Tuesday, February 1, 2022.

China Jo-Jo Drugstores, Inc., a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products, and healthcare provider in China, announced its financial results for the first half of fiscal year 2022 ended September 30, 2021.

TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, today announced the acquisition of Advera Health Analytics, the leader in pharmacovigilance software and data for detection, management, and mitigation of drug safety concerns.

Mr. Saunders will serve on Osmind’s Board of Directors and brings decades of leadership in healthcare and life sciences, including Chief Executive Officer and executive leadership roles at several prominent global pharmaceutical and healthcare companies.

Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics announced today that Bentrio™ has been approved by the Medical Device Authority of Malaysia and is, therefore, cleared for commercialization in that country.

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Medlab Middle East 2022 trade show held January 24-27 at the Dubai World Trade Centre.

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce that the Edith Cowan University, Perth, Australia, has published results from a study in ovarian cancer patients using the Parsortix® system.

FDA States Pivotal Clinical Trial May Proceed, Trial Expected to Commence By March 2022.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis with polyneuropathy.